Glaukos Corporation (GKOS) Stock Price
GKOSStock
$164.84+93.18%52W
Market Cap$9.72B
P/E—
PEG Ratio—
Div yield—
Beta0.73
GKOS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)26.87%
Price vs S&P 500 (4W)3.37%
VGM Score56.04
GKOS Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.21 | -$0.14 | +33.54%(+$0.07) | |
| Q1 2026 | -$0.28 | -$0.18 | +35.87%(+$0.10) | |
| Q4 2025 | -$0.20 | -$0.28 | -43.21%(-$0.08) | |
| Q3 2025 | -$0.26 | -$0.16 | +38.92%(+$0.10) | |
| Q2 2025 | -$0.26 | -$0.24 | +6.99%(+$0.02) |
GKOS Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.24
4.24
4.19
4.19
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
GKOSGlaukos Corporation | F | A | B | 15.9x | 17.7% | 79.1% | -31.6% | $164.84 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About Glaukos Corporation
Glaukos develops innovative ophthalmic therapies and devices for treating glaucoma, corneal disorders, and retinal diseases. The company commercializes the iStent family of micro-scale glaucoma surgical devices and the novel iDose TR intracameral implant, which delivers continuous glaucoma medication directly inside the eye as an alternative to daily eye drops. It also offers treatment for keratoconus, a rare corneal condition.